Palvella Therapeutics, Inc. (PVLA) EBIT (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed EBIT for 12 consecutive years, with -$1.5 million as the latest value for Q4 2024.
- On a quarterly basis, EBIT fell 111.06% to -$1.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$11.2 million, a 5.56% increase, with the full-year FY2024 number at -$14.1 million, down 18.75% from a year prior.
- EBIT was -$1.5 million for Q4 2024 at Palvella Therapeutics, up from -$5.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $13.4 million in Q4 2023 to a low of -$19.0 million in Q3 2021.
- A 5-year average of -$7.6 million and a median of -$9.2 million in 2021 define the central range for EBIT.
- Peak YoY movement for EBIT: crashed 833.16% in 2020, then soared 216.21% in 2023.
- Palvella Therapeutics' EBIT stood at -$12.4 million in 2020, then grew by 11.38% to -$11.0 million in 2021, then fell by 4.73% to -$11.5 million in 2022, then skyrocketed by 216.21% to $13.4 million in 2023, then plummeted by 111.06% to -$1.5 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's EBIT are -$1.5 million (Q4 2024), -$5.1 million (Q3 2024), and -$2.9 million (Q2 2024).